The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, ...

(“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings by a team of physician-scientists ...

Manojkumar Bupathi, MD, MS, discusses physician perspectives on treatment selection for frontline metastatic renal cell carcinoma (RCC) from a Case-Based Roundtable event.

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, Chinese Academy of Medical Sciences and Peking Union Medical College scientists co-presented a carbonic anhydrase IX ...

Metastasis is a major cause of mortality in patients with lung adenocarcinoma (LUAD), with the premetastatic niche (PMN) playing a crucial role in LUAD metastasis. However, the mechanisms underlying ...

Hepatocellular carcinoma cells impair T-cell activity by consuming lysine, which can be targeted with SLC3A2 inhibition or lysine supplementation as a therapeutic strategy to enhance antitumor ...

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in blood—which enriches cancer cells with an antioxidant shield to ...